How to design multi-target drugs: Target search options in cellular networks

Expert Opinion on Drug Discovery

Volumn 2, Issue 6, 2007, Pages 799-808

  Korcsmáros, Tamás ^a,b   Szalay, Máté S ^a,b   Böde, Csaba ^a   Kovács, István A ^a,b   Csermelyt, Péter ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Predinet Ltd   (Hungary)

Author keywords

Antibiotics; Disordered proteins; Drug targets; Fungicides; Genomics; Multi target drugs; Network damage; Networks; Pesticides; Phosphorylation; Protein kinases; Proteomics; Signaling networks

Indexed keywords

ANTIDEPRESSANT AGENT; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MEMANTINE; METFORMIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; POLYCLONAL ANTIBODY; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; SALICYLIC ACID DERIVATIVE;

BINDING AFFINITY; CELL ORGANELLE; CYTOSKELETON; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHOBICITY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DATABASE; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

EID: 34548065794     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.6.799     Document Type: Review

References (80)

1. BROWN D, SUPERTI-FURGA G: Rediscovering the sweet spot in drug discovery. Drug Discov. Today (2003) 8:1067-1077.
2. OVERINGTON JP, AL-LAZIKANI B, HOPKINS AL: How many drug targets are there? Nat. Rev. Drug Discov. (2006) 5:993-996.
3. SZUROMI P, VINSON V, MARSHALL E: Rethinking drug discovery. Science (2004) 303:1795.
4. BORISY AA, ELLIOTT PJ, HURST NW et al.: Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA (2003) 100:7977-7982.
5. DANCEY JE, CHEN HX: Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. (2006) 5:649-659.
6. KEITH CT BORISY AA, STOCKWELL BR: Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. (2005) 4:71-78.
7. MILLAN MJ: Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Therap. (2006) 110:135-370.
8. ZIMMERMANN GR, LEHAR J, KEITH CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today (2007) 12:34-42.
9. FITTER S, JAMES R. Deconvolution of a complex target using DNA aptamers. J. Biol. Chem. (2005) 280:34193-34201.
10. ROLLINGER JM, LANGER T, STUPPNER H: Strategies for efficient lead structure discovery from natural products. Curr. Med. Chem. (2006) 13:1491-1507.
11. SHAFIKHANI SH, ENGEL J: Pseudomonas aeruginosa type III-secreted toxin ExoT inhibits host-cell division by targeting cytokinesis at multiple steps. Proc. Natl. Acad. Sci. USA (2006) 103:15605-15610.
12. PAPP B, PAL C, HURST LD: Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast. Nature (2004) 429:661-664.
13. PAL C, PAPP B, LERCHER MJ, CSERMELY P, OLIVER SG, HURST LD: Chance and necessity in the evolution of minimal metabolic networks. Nature (2006) 440:667-670.
14. KITANO H: A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. (2007) 6:202-210.
15. SHAROM JR, BELLOWS DS, TYERS M: From large networks to small molecules. Curr. Op. Chem. Biol. (2004) 8:81-90.
16. FRANTZ S: Drug discovery: playing dirty. Nature (2005) 437:942-943.
17. HUANG S: Rational drug discovery: what can we learn from regulatory networks? Drug Discov. Today (2002) 7:S163-S169.
18. KAELIN WG JR: Gleevec: prototype or outlier? Science STKE (2004) (225), pe12.
19. MORPHY R, KAY C, RANKOVIC Z: From magic bullets to designed multiple ligands. Drug Discov. Today (2004) 9:641-651.
20. ROGAWSKI MA: Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - towards an understanding of their favorable tolerability. Amino Acids (2000) 19:133-149.
21. SATHORNSUMETEE S, VREDENBURGH KA, LATTIMORE KP, RICH JN: Malignant glioma drug discovery - targeting protein kinases. Expert Opin. Drug Discov. (2007) 2:1-17.
22. SOTI C, NAGY E, GIRICZ Z, VIGH L, CSERMELY P, FERDINANDY P: Heat shock proteins as emerging therapeutic targets. Br. J. Pharmacol. (2005) 146:769-780.
23. SREEDHAR AS, SOTI C, CSERMELY P: Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim. Biophys. Acta (2004) 1697:233-242.
24. YOUDIM MBH, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. (2005) 26:27-36.
25. SHARON J, LIEBMAN MA, WILLIAMS BR: Recombinant polyclonal antibodies for cancer therapy. J. Cell. Biochem. (2005) 96:305-313.
26. TODOROVSKA A, ROOVERS RC, DOLEZAL O, KORTT AA, HOOGENBOOM HR, HUDSON PJ: Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods (2001) 248:47-66.
27. BARABASI A-L, OLTVAI ZN: Network biology: understanding the cell's functional organization. Nat. Rev. Genet. (2004) 5:101-113.
28. BOCCALETTI S, LATORA V, MORENO Y, CHAVEZ M, HWANG D-U: Complex networks: structure and dynamics. Physics Rep. (2006) 424:175-308.
29. CSERMELY P: Weak Links: A Universal Key for Network Diversity and Stability. Springer Verlag, Heidelberg (2006). with > 800 original references.
30. BARABASI A-L, ALBERT R: Emergence of scaling in random networks. Science (1999) 286:509-512.
31. PALLA G, DERENYI I, FARKAS T, VICSEK T: Uncovering the overlapping community structure of complex networks in nature and society. Nature (2005) 435:814-818.
32. WATTS DJ, STOGATZ SH: Collective dynamics of 'small-world' networks. Nature (1998) 393:440-442.
33. ARITA M: The metabolic world of Escherichia coli is not small. Proc. Natl. Acad. Sci. USA (2004) 101:1543-1547.
34. TANAKA R, YI TM, DOYLE J: Some protein interaction data do not exhibit power law statistics. FEBS Lett. (2005) 579:5140-5144.
35. CHAUDHURI A, CHANT J: Protein-interaction mapping in search of effective drug targets. Bioessays (2005) 27:958-969.
36. TANIGUCHI CM, EMANUELLI B, KAHN CR: Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. (2006) 7:85-96.
37. SANTONICO E, CASTAGNOLI L, CESARENI G: Methods to reveal domain networks. Drug Discov. Today (2005) 10:1111-1117.
38. WILSON D, MADERA M, VOGEL C, CHOTHIA C, GOUGH J: The SUPERFAMILY database in 2007: families and functions. Nucleic Acids Res. (2007) 35:D308-D313.
39. KELL DB: Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov. Today (2006) 11:1085-1092.
40. MICHAELIS ML, SEYB KI, ANSAR S: Cytoskeletal integrity as a drug target. Curr. Alzheimer Res. (2005) 2:227-229.
41. VON MERING C, KRAUSE R, SNEL B et al.: Comparative assessment of large-scale data sets of protein-protein interactions. Nature (2002) 417:399-403.
42. SHEN J, ZHANG J, LUO X et al.: Predicting protein-protein interactions based only on sequences information. Proc. Natl. Acad. Sci. USA (2007) 104:4337-4341.
43. KIM PM, LU LJ, XIA Y, GERSTEIN MB: Relating three-dimensional structures to protein networks provides evolutionary insights. Science (2006) 314:1938-1941.
44. LIPTON SA: Turning down, but not off. Neuroprotection requires a paradigm shift in drug development. Nature (2004) 428:473.
45. CHENG Y, LEGALL T, OLDFIELD CJ et al.: Rational drug design via intrinsically disordered protein. Trends Biotechnol. (2006) 24:435-442.
46. CSERMELY P: Strong links are important, but weak links stabilize them. Trends Biochem. Sci. (2004) 29:331-334.
47. AMES BN: Low micronutrient intake may accelerate the degenerative diseases of azing through allocation of scarce micronutrients by triage. Proc. Natl. Acad. Sci. USA (2006) 103:17589-17594.
48. KLEIN P, PAWSON T, TYERS M: Mathematical modeling suggests cooperative interactions between a disordered polyvalent ligand and a single receptor site. Curr. Biol. (2003) 13:1669-1678.
49. NASH P, TANG X, ORLICKY S et al.: Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature (2001) 414:514-521.
50. KIRKWOOD TBL, KOWALD A: The network theory of aging. Exp. Gerontol. (1997) 32:395-399.
51. ALBERT R, JEONG H, BARABASI A-L: Attack and error tolerance of complex networks. Nature (2000) 406:378-382.
52. COHEN R, EREZ K, BEN-AVRAHAM D, HAVLIN S: Resilience of the Internet to random breakdowns. Phys. Rev. Lett. (2000) 85:4626-4628.
53. HOLME P, KIM BJ, YOON CN, HAN SK: Attack vulnerability of complex networks. Phys. Rev. E (2002) 65:056109.
54. FREEMAN LC: A set of measuring centrality based on betweenness. Sociometry (1977) 40:35-41.
55. AGOSTON V, CSERMELY P, PONGOR S: Multiple hits confuse complex systems: a genetic network as an example. Phys. Rev. E (2005) 71:051909.
56. LATORA V, MARCHIORI M: Efficient behavior of small-world networks. Phys. Rev. Lett. (2001) 87:198701.
57. LATORA V, MARCHIORI M: Vulnerability and protection of infrastructure networks. Phys. Rev. E (2005) 71:015103.
58. DALL'ASTA L, BARRAT A, BARTHÉLEMY M, VESPIGNANI A: Vulnerability of weighted networks. J. Stat. Mech. (2006) P04006.
59. MOTTER AE, NISHIKAWA T, LAI Y: Range-based attack on links in scale-free networks: are long-range links responsible for the small-world phenomenon? Phys. Rev. E (2002) 66:065103.
60. CASCANTE M, BOROS LG, COMIN-ANDUIX B, DE ATAURI P, CENTELLES JJ, LEE PWN: Metabolic control analysis in drug discovery and disease. Nat. Biotechnol. (2002) 20:243-249.
61. CORNISH-BOWDEN A, CARDENAS ML: Metabolic analysis in drug design. C. R. Biol. (2003) 326:509-515.
62. DUARTE NC, BECKER SA, JAMSHIDI N et al.: Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc. Natl. Acad. Sci. USA (2007) 104:1777-1782.
63. BERGMANN S, IHMELS J, BARKAI N: Similarities and differences in genome-wide expression data of six organisms. PLoS Biol. (2004) 2:85-93 (E9).
64. STUART JM, SEGAL E, KOLLER D, KIM SK: A gene-coexpression network for global discovery of conserved genetic modules. Science (2003) 302:249-255.
65. ARCHAKOV AI, GOVORUN VM, DUBANOV AV et al.: Protein-protein interactions as a target for drugs in proteomics. Proteomics (2003) 3:380-391.
66. AOYAMA T, SUZUKI Y, ICHIKAWA H: Neural networks applied to quantitative structure-activity relationship analysis. J. Med. Chem. (1990) 33:2583-2590.
67. CSERMELY P, AGOSTON V, PONGOR S: The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. (2005) 26:187-182.
68. HORNBERG JJ, BRUGGEMAN FJ, WESTERHOFF HV, LANKELMA J: Cancer: a systems biology disease. Biosystems (2006) 83:81-90.
69. PALOP JJ, CHIN J, MUCKE L: A network dysfunction perspective on neurodegenerative diseases. Nature (2006) 443:768-773.
70. CSERMELY P, SOTI C: Aging cellular networks: chaperones as major participants. Exp. Gerontol. (2007) 42:113-119.
71. GARDNER TS, DI BERNARDO D, LORENZ D, COLLINS JJ: Inferring genetic networks and identifying compound mode of action via expression profiling. Science (2003) 301:102-105.
72. GIAEVER G, FLAHERTY P, KUMM J et al.: Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. Proc. Natl. Acad. Sci. USA (2004) 101:793-798.
73. LUM PY, ARMOUR CD, STEPANIATS SB et al.: Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygores. Cell (2004) 116:121-137.
74. PARSONS AB, LOPEZ A, GIVONI IE et al.: Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell (2006) 126:611-625.
75. IN VIVO PHARMACOLOGY TRAINING GROUP: The fall and rise of in vivo pharmacology. Trends Pharmacol. (2002) 23:13-18.
76. GOLDBERGER AL, AMARAL LAN, HAUSDORF JM, IVANOV PC, PENG C-K, STANLEY HE: Fractal dynamics in physiology: alterations with disease and aging. Proc. Natl. Acad. Sci. USA (2002) 99:2466-2472.
77. SZALAY M, KOVACS IA, KORCSMAROS T, BODE C, CSERMELY P: Stress-induced rearrangements of cellular networks: consequences for protection and drug design. FEBS Lett. (in press), arxiv.org/q-bio.MN/0702006.
78. HALLEN K, BJORKEGREN J, TEGNER J: Detection of compound mode of action by computational integration of whole-genome measurements and genetic perturbations. BMC Bioinformatics (2006) 7:51.
79. KHOLODENKO BN, KIYATKIN A, BRUGGEMAN FJ, SONTAG E, WESTERHOFF HV, HOEK JB: Untangling the wires: a strategy to trace functional interactions in signaling and gene networks. Proc. Natl. Acad. Sci. USA (2002) 99:12841-12846.
80. TEGNÉR J, YEUNG MK, HASTY J, COLLINS JJ: Reverse engineering gene networks: integrating genetic perturbations with dynamical modeling. Proc. Natl. Acad. Sci. USA (2003) 100:5944-5949.